<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701699</url>
  </required_header>
  <id_info>
    <org_study_id>UHN REB 13-6528-C</org_study_id>
    <nct_id>NCT02701699</nct_id>
  </id_info>
  <brief_title>18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer</brief_title>
  <official_title>A Feasibility Study of Hypoxia Imaging in Patients With Lung Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look for low levels of oxygen (hypoxia) in lung cancer using&#xD;
      a positron emission tomography (PET) scan. Hypoxia can influence how lung cancer grows and&#xD;
      responds to treatments like radiotherapy and chemotherapy. The use of PET scans to measure&#xD;
      hypoxia may be better and simpler than the approaches used previously. This study will assess&#xD;
      whether or not PET scans can provide useful information about hypoxia in lung cancer.&#xD;
&#xD;
      In this study, a radiotracer called Fluoroazomycin Arabinoside (FAZA) will be used to measure&#xD;
      hypoxia in the patient's tumour. FAZA has already been used in many cancers including lung&#xD;
      cancer. Patients who consent to participate in this trial will receive 1 FAZA PET Scan prior&#xD;
      to their first radiotherapy treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with lung cancer using the PET tracer FAZA to image primary tumor hypoxia prior to treatment with radiotherapy</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with lung cancer using 4D (gated) and static PET imaging of FAZA uptake</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of the volume of injected FAZA tracer taken up in the tumor prior to treatment with radiotherapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>18-F-FAZA Scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>18-F-FAZA</intervention_name>
    <description>All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction</description>
    <arm_group_label>18-F-FAZA Scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years&#xD;
&#xD;
          2. Patients with stage II or III lung cancer (both NSCLC and SCLC) qualifying for&#xD;
             radiotherapy to the primary tumor, with or without treatment of mediastinal or hilar&#xD;
             lymph nodes&#xD;
&#xD;
          3. Intention to treat using radiotherapy according to the current treatment policies of&#xD;
             the PMH Lung Group&#xD;
&#xD;
          4. Concurrent systemic therapy allowed&#xD;
&#xD;
          5. A negative serum pregnancy test within the two week interval immediately prior to&#xD;
             PET-CT imaging, in women of child-bearing age&#xD;
&#xD;
          6. Ability to provide written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous radiotherapy to intended treatment volumes.&#xD;
&#xD;
          2. Previous systemic therapy&#xD;
&#xD;
          3. Active malignancy other than lung cancer&#xD;
&#xD;
          4. Unable to remain supine for more than 60 minutes&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
          6. Age less than 18 years old&#xD;
&#xD;
          7. Failure to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network--Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alex Sun, MD</last_name>
    <phone>416 946 4501</phone>
    <phone_ext>2126</phone_ext>
    <email>Alex.Sun@rmp.uhn.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Breen, PhD</last_name>
    <phone>416 946 4501</phone>
    <phone_ext>5812</phone_ext>
    <email>Stephen.Breen@rmp.uhn.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Network, Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Sun, MD</last_name>
      <phone>416 946 4501</phone>
      <phone_ext>2126</phone_ext>
      <email>Alex.Sun@rmp.uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Stephen Breen, PhD</last_name>
      <phone>416 946 4501</phone>
      <phone_ext>5812</phone_ext>
      <email>Stephen.Breen@rmp.uhn.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Alex Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>FAZA PET Imaging</keyword>
  <keyword>Lung Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoroazomycin arabinoside</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

